WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > eHealth Initiative
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Fiercepharma | June 17, 2020
On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two doze...
PHARMA TECH
PR Newswire | January 23, 2024
CGI, one of the largest business and IT consulting companies in the world, today announced a partnership with Körber aimed at enabling pharmaceutical and life sciences companies to improve their production processes by combining CGI's end-to-end services with Körber's Werum PAS-X Manufacturing Execution System (MES) Suite. The global partnership is designed to help clients increase efficiency, accuracy, and safety in pharma products and enhance decision-making through acc...
BioSpace | April 16, 2020
In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic. Now the company hopes to launch a clinical trial testing the efficacy of the drug in patients. In the in vitro tests, Ryanodex demonstrated antiviral activity and a lack of cytotoxicity. Two days after dosing, the in vitro results showed an absence of cytopathic effects in the infected cells. This ...
Research
Regeneron | November 24, 2020
Covid-19 Regeneron antibody cocktail, one of the drugs of President Donald Trump was given after he was infected with the SARS-COV-02 virus, had been cleaned for emergency use by the FDA. And, despite the towering vaccine slide, one analyst still sees therapy as a $ 1 billion-plus business. Authorization of Emergency Use (EUA) for Regn-COV2, a combination of monoclonal antibodies Kasarivimab and IMdevimab, marked the second for antibody therapy. The first to go to Bamlanivimab Eli...
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE